Wegovy won MASH approval in August 2025, turning a pre-launch window into a Year 0 to Year 1 retention fight against Rezdiffra.

MASH, the progressive inflammatory form of fatty liver disease, was renamed from NASH under the 2023 multi-society consensus. The FDA-defined treatable population is US adults with noncirrhotic MASH and moderate-to-advanced fibrosis, stages F2 to F3, roughly 6.7 million people. Two drugs now hold FDA accelerated approval for that exact label: Rezdiffra (resmetirom), an oral THR-beta agonist from Madrigal, approved March 2024, and Wegovy (semaglutide 2.4mg), a GLP-1 from Novo Nordisk, approved August 2025.

The common assumption that semaglutide is a future 2027 entrant is wrong: it is already competing with Rezdiffra today. On their placebo-controlled endpoints, semaglutide shows stronger resolution, 62.9% versus 34.3%, and greater weight loss, while Rezdiffra's defensible ground is its direct fibrosis-targeted mechanism, oral convenience and an earlier Medicare price-negotiation horizon under the IRA. The strategic move is to lock preferred formulary tier and first-line prior authorization tied to FIB-4 or elastography-confirmed fibrosis before GLP-1 data harden guideline preference.

The oral, liver-specific mechanism is easier to wall off than a GLP-1 with obesity spillover demand.

Five questions this report answers:

Q1 - Is the semaglutide threat still ahead of us, or is Wegovy already competing with Rezdiffra today?

Q2 - Where does Rezdiffra still win a clinical argument against semaglutide's stronger resolution and weight-loss data?

Q3 - How can commercial teams lock preferred payer access before GLP-1 data shift guideline preference?

Q4 - Why does resmetirom face an earlier IRA Medicare price-negotiation clock than a biologic GLP-1?

Q5 - Which pipeline agents, including lanifibranor and the FGF21 class, are chasing the compensated-cirrhosis segment neither drug covers?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#MASH #US #CompetitiveIntelligence #AXLRx #LiverDisease

Live report page:  https://axlrx.ai/mash/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/